BMY Stock Recent News
BMY LATEST HEADLINES
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.49, signifying a -0.3% move from its prior day's close.
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
The U.S. Food and Drug Administration's staff reviewers on Wednesday raised safety concerns over the use of Johnson & Johnson's and Bristol-Myers Squibb's cancer therapies as earlier treatments for blood cancer patients.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024.
Bristol-Myers Squibb has returned to sales growth after a period of declining sales, signaling a turnaround ahead. The biopharma continues to be hit by key drugs facing LOEs, but new drugs and acquisitions show promising sales ramps. The stock trades at ~7x 2025 EPS targets with more upside as dilutive deals in 2024 start to pay off.
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
Bristol-Myers Squibb's stock has gained momentum after a difficult 2023, suggesting a positive outlook for the company.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Upcoming Investor Conferences.
If you're searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out.